Complete Response to Erlotinib Treatment in Brain Metastases from Recurrent NSCLC

Overview

Journal Thorax

Date 2006 Jan 7

PMID 16396957

Citations 23

Authors

C S L Lai

C Boshoff

M Falzon

S M Lee

Affiliations

Soon will be listed here.

Citing Articles

Long-Term Survival of a Patient With Late-Stage Non-Small Cell Lung Cancer.

Allan-Blitz L, Hashemi L Fed Pract. 2019; 33(Suppl 5):63S-65S.

PMID: 30766226 PMC: 6375520.

The impact of EGFR mutations on the incidence and survival of stages I to III NSCLC patients with subsequent brain metastasis.

Chang W, Wu Y, Su P, Yang S, Lin C, Su W PLoS One. 2018; 13(2):e0192161.

PMID: 29447182 PMC: 5813924. DOI: 10.1371/journal.pone.0192161.

Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future.

Proto C, Imbimbo M, Gallucci R, Brissa A, Signorelli D, Vitali M Transl Lung Cancer Res. 2017; 5(6):563-578.

PMID: 28149752 PMC: 5233868. DOI: 10.21037/tlcr.2016.10.16.

Survival of patients with brain metastases from non-small cell lung cancer harboring EGFR mutations treated with epidermal growth factor receptor tyrosine kinase inhibitors.

Kashima J, Okuma Y, Miwa M, Hosomi Y Med Oncol. 2016; 33(11):129.

PMID: 27757781 DOI: 10.1007/s12032-016-0843-8.

Icotinib as initial treatment in lung adenocarcinoma patients with brain metastases.

Xu J, Liu X, Yang S, Zhang C, Wang L, Shi Y Thorac Cancer. 2016; 7(4):437-41.

PMID: 27385986 PMC: 4930963. DOI: 10.1111/1759-7714.12351.

References

Cappuzzo F, Ardizzoni A, Soto-Parra H, Gridelli C, Maione P, Tiseo M . Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC). Lung Cancer. 2003; 41(2):227-31. DOI: 10.1016/s0169-5002(03)00189-2. View

Fabian M, Biggs 3rd W, Treiber D, Atteridge C, Azimioara M, Benedetti M . A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol. 2005; 23(3):329-36. DOI: 10.1038/nbt1068. View

Tsao M, Sakurada A, Cutz J, Zhu C, Kamel-Reid S, Squire J . Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med. 2005; 353(2):133-44. DOI: 10.1056/NEJMoa050736. View

Shepherd F, Pereira J, Ciuleanu T, Tan E, Hirsh V, Thongprasert S . Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005; 353(2):123-32. DOI: 10.1056/NEJMoa050753. View

Pao W, Miller V . Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol. 2005; 23(11):2556-68. DOI: 10.1200/JCO.2005.07.799. View